Skip to Content

Real-World Data on Avelumab as 1L Maintenance Treatment

In this MEDtalk, Dr. Philippe Barthelemy from the ICANS Institute in Strasbourg, discusses the results from the AVENANCE study with real-world data from France. The study confirms the effectiveness and safety of avelumab as a safe standard of care for patients with advanced urothelial carcinoma.

Philippe Barthelemy

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top